The call highlighted significant progress in regulatory strategies and product pipeline advancements, especially with the potential accelerated approval path for Iopofosine I-131. However, the notable decrease in R&D and administrative expenses and an increased net loss indicate financial challenges. Overall, the sentiment is cautiously optimistic but tempered by financial concerns.

Company Guidance

During the Cellectar Biosciences Second Quarter 2025 Financial Results and Business Update Conference Call, the company provided guidance on several key metrics. Cellectar plans to submit a New Drug Application (NDA) for iopofosine I-131 under an accelerated approval pathway with the FDA, contingent on sufficient funding and a confirmatory study being underway. The company has been granted breakthrough therapy designation by the FDA and prime designation by the EMA for this treatment. Financially, Cellectar ended the quarter with $11 million in cash, following a recent $5.8 million fundraise, and expects this to support operations into the second quarter of 2026. Research and development expenses decreased to $2.4 million from $7.3 million year-over-year due to the conclusion of patient enrollment and follow-up for the CLOVER-WaM Phase II study. The company reported a net loss of $5.4 million, impacted by noncash warrant activities. They anticipate rapid study enrollment for the confirmatory trial and are poised to advance their radiopharmaceutical pipeline, including CLR 125 and CLR 225, pending further funding.

Regulatory Strategy for Iopofosine I-131

Cellectar plans to submit a New Drug Application (NDA) under an accelerated approval pathway for Iopofosine I-131 as a treatment for Waldenstrom's Macroglobulinemia (WM) with FDA breakthrough therapy designation and PRIME designation in Europe.

Financial Position and Funding

Cellectar raised nearly $10 million through recent financings and ended the quarter with $11 million in cash, adequate to fund operations into the second quarter of 2026.

Progress in Radiopharmaceutical Pipeline

Cellectar is on track to initiate Phase I trials for CLR 125 and CLR 225, targeting triple-negative breast cancer and solid tumors such as pancreatic cancer, respectively.

Cellectar Biosciences (CLRB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CLRB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-2.53 / -	-12	―	―	―
Aug 14, 2025	2025 (Q2)	-3.72 / -3.39	-5.4	37.22% (+2.01)	―
May 13, 2025	2025 (Q1)	-4.90 / -4.20	-22.2	81.08% (+18.00)	―
Mar 13, 2025	2024 (Q4)	-10.57 / -2.10	-12.3	82.93% (+10.20)	―
Nov 18, 2024	2024 (Q3)	-9.90 / -12.00	-26.083	53.99% (+14.08)	―
Aug 13, 2024	2024 (Q2)	-9.60 / -5.40	-21.9	75.34% (+16.50)	―
May 14, 2024	2024 (Q1)	-14.80 / -22.20	-22.8	2.63% (+0.60)	―
Mar 27, 2024	2023 (Q4)	-17.10 / -12.30	-16.5	25.45% (+4.20)	―
Nov 02, 2023	2023 (Q3)	-15.75 / -26.08	-38.4	32.08% (+12.32)	―
Aug 14, 2023	2023 (Q2)	-19.10 / -21.90	-36.6	40.16% (+14.70)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CLRB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$4.42	$4.42	0.00%
May 13, 2025	$7.92	$7.20	-9.09%
Mar 13, 2025	$9.50	$8.99	-5.37%
Nov 18, 2024	$55.80	$53.10	-4.84%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cellectar Biosciences (CLRB) report earnings?

Cellectar Biosciences (CLRB) is schdueled to report earning on Oct 30, 2025, TBA (Confirmed).

What is Cellectar Biosciences (CLRB) earnings time?

Cellectar Biosciences (CLRB) earnings time is at Oct 30, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CLRB EPS forecast?

CLRB EPS forecast for the fiscal quarter 2025 (Q3) is -2.53.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing